A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response.
Daniela RossiSavinio SciasciaIrene CecchiMarta SaraccoErika MontaboneVittorio ModenaRaffaele PelleritoRenato CarignolaDario RoccatelloPublished in: Journal of clinical medicine (2021)
Our findings support that the IBCDT was well tolerated and might be a promising therapeutic option for the management of SSc, especially in those subjects with multiorgan involvement that includes ILD.